QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
7.32B
Market cap7.32B
Price-Earnings ratio
18.36
Price-Earnings ratio18.36
Dividend yield
0.74%
Dividend yield0.74%
Average volume
2.36M
Average volume2.36M
High today
$35.55
High today$35.55
Low today
$35.09
Low today$35.09
Open price
$35.29
Open price$35.29
Volume
1.51M
Volume1.51M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$32.53
52 Week low$32.53

Stock Snapshot

With a market cap of 7.32B, QIAGEN(QGEN) trades at $35.54. The stock has a price-to-earnings ratio of 18.36 and currently yields dividends of 74.0%.

On 2026-05-27, QIAGEN(QGEN) stock moved within a range of $35.09 to $35.55. With shares now at $35.54, the stock is trading +1.3% above its intraday low and -0.0% below the session's peak.

Trading activity shows a volume of 1.51M, compared to an average daily volume of 2.36M.

The stock's 52-week range extends from a low of $32.53 to a high of $57.82.

The stock's 52-week range extends from a low of $32.53 to a high of $57.82.

QGEN News

Simply Wall St 11h
Does QuantiFERON Guidance Cut and Shareholder Probe Change The Bull Case For Qiagen?

In May 2026, Qiagen revised its growth guidance for its QuantiFERON tuberculosis testing product, prompting a shareholder rights investigation by Bronstein, Gew...

Does QuantiFERON Guidance Cut and Shareholder Probe Change The Bull Case For Qiagen?
TipRanks 11h
Norges Bank Discloses 2.44% Stake in QIAGEN

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Simply Wall St 3d
Assessing Qiagen Valuation After New AI Assistant Launch And Expanded NVIDIA Collaboration

Qiagen (NYSE:QGEN) has put AI at the center of its story this month by launching the QIA Agent digital assistant for lab workflows and expanding its AI collabor...

Assessing Qiagen Valuation After New AI Assistant Launch And Expanded NVIDIA Collaboration

Analyst ratings

62%

of 21 ratings
Buy
38.1%
Hold
61.9%
Sell
0%

More QGEN News

Nasdaq 6d
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform

QIAGEN QGEN recently launched QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify products, access techni...

QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
Simply Wall St 7d
Qiagen Faces Legal Review As QuantiFERON Outlook Shifts And Valuation Draws Focus

A law firm has launched an investigation into Qiagen (NYSE:QGEN) following the company’s revision of its growth expectations for QuantiFERON sales. The review...

Qiagen Faces Legal Review As QuantiFERON Outlook Shifts And Valuation Draws Focus

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.